Compare Crescent Energy Company Class A Common Stock (CRGY) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crescent Energy Company Class A Common Stock vs Charles River Laboratories Intl. Inc — how do they compare? Crescent Energy Company Class A Common Stock trades at $12.71 (market cap $4.30B), while Charles River Laboratories Intl. Inc trades at $302.17 (market cap $14.23B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 3.3× Crescent Energy Company Class A Common Stock's market cap, and Crescent Energy Company Class A Common Stock pays a 3.69% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crescent Energy Company Class A Common Stock for 1 Days and Charles River Laboratories Intl. Inc for 33 Days on average.
| CRGY | CRL | |
|---|---|---|
Market Cap | $4.30B | $14.23B |
Volume | 15,201,625 | 1,176,885 |
Sector | Energy | Health |
52-Week High | $15.37 | $310.77 |
52-Week Low | $7.75 | $149.93 |
Typical Hold Time | 1 Days | 33 Days |
Enterprise Value | $9.31B | $17.06B |
Dividend Yield | 3.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Crescent Energy Company Class A Common Stock
Crescent Energy acquires, develops, and produces oil and natural gas from onshore U.S. basins. Its portfolio includes producing assets with oil and natural gas exposure.
Read more on CRGY →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
